Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rifamycin Sodium

FDA-approved product (tablet, delayed release, oral), marketed as Aemcolo.

Registered studies
43
Lab records
6
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Rifamycin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diarrhea
  • Eye infection
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics; Other antibiotics for topical use; Antiinfectives
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AB03; WHO ATC A07AA13; WHO ATC D06AX15; WHO ATC S01AA16

Repurposing investigation

Rifamycin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA96.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli74.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae16.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis93.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

43registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 2 of 2 lab records
  • E. coli: measured active in 1 of 2 lab records
  • K. pneumoniae: measured active in 0 of 1 lab record
  • M. tuberculosis: measured active in 1 of 1 lab record
Open Rifamycin Sodium in ChEMBL Registered studies below
Show the 6 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rifamycin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Fecal Microbiota Transplantation for the Treatment of Refractory Hepatic Encephalopathy After TIPS Surgery

    NCT07683936 · start 2026-06-01

    Registered record
    Registry ID
    NCT07683936
    Conditions
    Hepatic Encephalopathy; Fecal Microbiota Transplantation; TIPS; Refractory Hepatic Encephalopathy
    Interventions
    Fecal Microbiota Transplantation; Rifaximin、Lactulose; Dietary Fiber Prebiotic
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2026-06-01
    Completion
    2028-06-01
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Encephalopathy; Fecal Microbiota Transplantation; TIPS; Refractory Hepatic Encephalopathy
    InterventionFecal Microbiota Transplantation; Rifaximin、Lactulose; Dietary Fiber Prebiotic
    PhaseEarly phase 1
    Registry statusRecruiting

  • Evaluation of the Outcome of Fecal Microbiota Transplantation

    NCT07454408 · start 2026-03-07

    Registered record
    Registry ID
    NCT07454408
    Conditions
    Hepatic Encephalopathy; Fecal Microbiota Transplantation; TIPS
    Interventions
    Fecal Microbiota Transplantation; FMT Matched Placebo; Rifaximin、Lactulose
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-03-07
    Completion
    2028-06-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Encephalopathy; Fecal Microbiota Transplantation; TIPS
    InterventionFecal Microbiota Transplantation; FMT Matched Placebo; Rifaximin、Lactulose
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • Drug-drug Interaction Study of Rifampin and Anaprazole Sodium

    NCT07330531 · start 2026-01-04

    Registered record
    Registry ID
    NCT07330531
    Conditions
    Drug-drug Interaction Study
    Interventions
    Anelazol Sodium Enteric-coated Tablets; Rifampicin Capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-01-04
    Completion
    2027-07-21
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-drug Interaction Study
    InterventionAnelazol Sodium Enteric-coated Tablets; Rifampicin Capsules
    PhasePhase 4
    Registry statusNot yet recruiting

  • A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults

    NCT07066722 · start 2025-07-07

    Registered record
    Registry ID
    NCT07066722
    Conditions
    HIV Infections
    Interventions
    VH4524184; Itraconazole; Rifabutin; Phenytoin; Metformin; Digoxin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-07-07
    Completion
    2025-12-17
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionVH4524184; Itraconazole; Rifabutin; Phenytoin +2 more
    PhasePhase 1
    Registry statusCompleted

  • Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction

    NCT06652087 · start 2024-09-02

    Registered record
    Registry ID
    NCT06652087
    Conditions
    Bacterial Overgrowth Syndrome Small Bowel; Heart Failure with Preserved Ejection Fraction
    Interventions
    Rifaximin; Standard HFpEF treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-09-02
    Completion
    2027-09-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Overgrowth Syndrome Small Bowel; Heart Failure with Preserved Ejection Fraction
    InterventionRifaximin; Standard HFpEF treatment
    PhaseNot applicable
    Registry statusRecruiting

  • Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years

    NCT04026984 · start 2024-06

    Registered record
    Registry ID
    NCT04026984
    Conditions
    Traveler's Diarrhea
    Interventions
    Rifamycin SV-MMX; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2024-06
    Completion
    2025-12
    Enrolment
    142

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTraveler's Diarrhea
    InterventionRifamycin SV-MMX; Placebo
    PhasePhase 2
    Registry statusUnknown

  • Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease

    NCT05021731 · start 2024-04-20

    Registered record
    Registry ID
    NCT05021731
    Conditions
    Latent Tuberculosis; Kidney Failure
    Interventions
    Rifampicin plus Isoniazid; Rifapentine plus Isoniazid; Rifampicin alone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2024-04-20
    Completion
    2025-04-30
    Enrolment
    225

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLatent Tuberculosis; Kidney Failure
    InterventionRifampicin plus Isoniazid; Rifapentine plus Isoniazid; Rifampicin alone
    PhasePhase 4
    Registry statusUnknown

  • Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years

    NCT04027894 · start 2024-01

    Registered record
    Registry ID
    NCT04027894
    Conditions
    Traveler's Diarrhea
    Interventions
    Rifamycin SV MMX; Placebo to Rifamycin SV-MMX
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2024-01
    Completion
    2025-12
    Enrolment
    142

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTraveler's Diarrhea
    InterventionRifamycin SV MMX; Placebo to Rifamycin SV-MMX
    PhasePhase 2
    Registry statusUnknown

  • A Drug-drug Interaction Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Methotrexate in Elderly Subjects

    NCT06108453 · start 2023-08-21

    Registered record
    Registry ID
    NCT06108453
    Conditions
    Drug Interactions
    Interventions
    Methotrexate Sodium; Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2023-08-21
    Completion
    2024-11-24
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Interactions
    InterventionMethotrexate Sodium; Rifampicin
    PhasePhase 1
    Registry statusUnknown

  • A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis

    NCT05575518 · start 2023-08-11

    Registered record
    Registry ID
    NCT05575518
    Conditions
    Tuberculosis; Human Immunodeficiency Virus
    Interventions
    Optimised rifamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2023-08-11
    Completion
    2026-03-31
    Enrolment
    414

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Human Immunodeficiency Virus
    InterventionOptimised rifamycin
    PhasePhase 3
    Registry statusUnknown

  • The Safety, Completion Rate and Prevention Effect by Rifamycin-containing Regimens for Latent Tuberculosis Infection in Patients With Kidney Transplantation: a Prospective Intervention Pilot Study

    NCT05588492 · start 2022-01-01

    Registered record
    Registry ID
    NCT05588492
    Conditions
    Pulmonology
    Interventions
    Rifamycin-containing regimen; Rifamycin-free regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-01-01
    Completion
    2026-12-31
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonology
    InterventionRifamycin-containing regimen; Rifamycin-free regimen
    PhasePhase 4
    Registry statusRecruiting

  • Topical Rifamycin SV for Wound Healing After Sapphire FUE Hair Transplantation

    NCT07155408 · start 2021-12-02

    Registered record
    Registry ID
    NCT07155408
    Conditions
    Androgenetic Alopecia; Wound Healing
    Interventions
    Povidone-Iodine 10%; Rifamycin SV Sodium
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-12-02
    Completion
    2022-06-22
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAndrogenetic Alopecia; Wound Healing
    InterventionPovidone-Iodine 10%; Rifamycin SV Sodium
    PhaseNot applicable
    Registry statusCompleted

  • Fruquintinib CYP3A Inhibitor and Inducer Study

    NCT04557397 · start 2020-09-02

    Registered record
    Registry ID
    NCT04557397
    Conditions
    Drug Drug Interaction
    Interventions
    Fruquintinib; Itraconazole; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-09-02
    Completion
    2020-10-18
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Drug Interaction
    InterventionFruquintinib; Itraconazole; Rifampin
    PhasePhase 1
    Registry statusCompleted

  • Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)

    NCT04501380 · start 2020-06-30

    Registered record
    Registry ID
    NCT04501380
    Conditions
    Small Intestinal Bacterial Overgrowth; Gastrointestinal Disease; Gastrointestinal Infection
    Interventions
    AEMCOLO (Rifamycin SV MMX)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-06-30
    Completion
    2022-12-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall Intestinal Bacterial Overgrowth; Gastrointestinal Disease; Gastrointestinal Infection
    InterventionAEMCOLO (Rifamycin SV MMX)
    PhasePhase 2
    Registry statusUnknown

  • Comparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) Trial

    NCT04095663 · start 2019-10-01

    Registered record
    Registry ID
    NCT04095663
    Conditions
    Diverticulitis
    Interventions
    Partial Colectomy; Medical Management
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2019-10-01
    Completion
    2027-02-01
    Enrolment
    255

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiverticulitis
    InterventionPartial Colectomy; Medical Management
    PhaseNot applicable
    Registry statusActive not recruiting